Early access
Sign in
Taking people in United StatesNo phase

Compares an MRI scan with a bladder tumor biopsy procedure in suspected bladder cancer

Tests whether an MRI scan accurately shows muscle-invasive bladder cancer, compared with tumor removal.

Key facts

Who runs it
University of California, Irvine
Where
Orange, United StatesSee the site
Trial code
Registry title
mpMRI Compared to Diagnostic TURBT in Patients With Suspected Muscle-Invasive Bladder Cancer
Status
Recruiting
People taking part
30 people, planned
Started
27 Mar 2024
Expected to end
Apr 2030
Type of study
Interventional
Treatments tested
  • mpMRI + Diagnostic TURBT
Record updated
4 May 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults whose doctor suspects bladder cancer that has grown into the muscle wall. It compares MRI scans with a surgical bladder tumor removal (TURBT) for finding out the stage.

Age
18 years or older
Sex
All sexes can join
Disease stage
Suspected muscle-invasive bladder cancer, judged from how the tumor looks on a first routine cystoscopy. ECOG Performance Status of 0-3.
Earlier treatment
No TURBT within 120 days before joining. No therapy for bladder cancer within 180 days before joining.

Main reasons for not taking part

  • TURBT within the last 120 days
  • Therapy for bladder cancer within the last 180 days
  • Cannot tolerate mpMRI or its contrast
  • Cannot tolerate TURBT or its anesthesia
  • ECOG Performance Status of 4

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Age 18 years old or greater at the time of consent
  • Suspected muscle-invasive bladder cancer by tumor appearance on initial routine cystoscopy as determined by the UCI-affiliated provider performing this procedure
  • ECOG Performance Status of 0-3
  • Patients must have the ability to understand and the willingness to sign a written informed consent document (prior to the initiation of the study and any study procedures)
  • Patients must be willing and able to comply with the scheduled visits, imaging plan, follow up plan, and other specified study procedures in the opinion of the Investigator

Who cannot take part

  • Prior TURBT within 120 days of study entry
  • Prior therapy for bladder cancer within 180 days of study entry
  • Inability to tolerate mpMRI or associated contrast
  • Inability to tolerate TURBT or associated anesthesia
  • ECOG Performance Status of 4
  • Female patient who is known to be pregnant or breastfeeding

Where in United States

  • Chao Family Comprehensive Cancer Center, University of California, IrvineOrange, United StatesContact: Nataliya Mar, MDTaking people

About the trial

What the trial wants to find out

This is a pilot, single arm, prospective study that aims to validate the accuracy of the VI-RADS score obtained via multi-parametric magnetic resonance imaging (mpMRI) compared to pathologic cancer stage obtained via diagnostic transurethral bladder tumor resection (TURBT) as well as compare the clinical and quality of life outcomes between these diagnostic modalities in patients with suspected muscle-invasive bladder cancer (MIBC).

The group in the trial

  • mpMRI + Diagnostic TURBTTreatment being tested

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Outcomes With Multi Parametric MRI (mpMRI) Compared to Diagnostic Transurethral Resection of Bladder Tumor (TURBT) in Patients With Suspected Muscle-Invasive Bladder Cancer - a Pilot Study
Plain-language title
Compares an MRI scan with a bladder tumor biopsy procedure in suspected bladder cancerGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
4 May 2026